PaulRWalkerMDFACP

Oncology • Carmel, IN

Hematologic Oncology, Thoracic Cancer

Chief Medical Officer, CIRCULOGENE Associate Professor Emeritus Brody School of Medicine at East Carolina University

Join to view full profile

Dr. Walker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Walker's full profile

Already have an account?

Office
15468 Mission Hills Dr
Carmel, IN 46033

Education & Training

University of ToledoFellowship, Hematology and Medical Oncology, 1991 - 1993
Indiana University School of Medicine/Ball MemorialResidency, Internal Medicine, 1979 - 1983
Indiana University School of MedicineClass of 1979

Certifications & Licensure

IN State Medical License 1979 - 2025
NC State Medical License 2006 - 2023
OH State Medical License 2004 - 2009
American Board of Internal Medicine Internal Medicine

Clinical Trials

Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC Start of enrollment: 2007 Feb 01
Terminated
Phase 2
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
Completed
Phase 2
Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention Start of enrollment: 2012 Aug 01
Completed
Not Applicable
Treating NSCLC Minimal Stage IV With Curative Intent Start of enrollment: 2013 Jun 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

221 citations
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Chipman Rg Stroud, Aparna Madhukeshwar Hegde, Cynthia R. Cherry, Abdul Rafeh Naqash, Nitika Sharma
Journal of Oncology Pharmacy Practice. 2019-04-01
32 citations
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global coh...
Abdul Rafeh Naqash, Biagio Ricciuti, Dwight H Owen, Vaia Florou, Yukihiro Toi
Cancer Immunology, Immunotherapy. 2020-07-01
13 citations
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
Patricia Rich, R. Brian Mitchell, Eric Scott Schaefer, Paul R. Walker, J. Dubay
Journal for Immunotherapy of Cancer. 2021-10-01

Press Mentions

The Use of Liquid Biopsies in Patients with NSCLCNovember 15th, 2017